\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ will\\ most\\ likely\\ receive\\ treatment\\ with\\ a\\ cholinesterase\\ inhibitor\\ \\(eg\\ tacrine\\ or\\ cognex\\)\\ which\\ may\\ delay\\ cognitive\\ decline\\ in\\ the\\ early\\ to\\ mid\\ stages\\ of\\ the\\ disease\\.\ \(0\)\
\-\ pet\\ fluorine\\-18\\ fluorodeoxyglucose\\ scan\\ with\\ high\\ resolution\\ axial\\,\\ sagittal\\,\\ and\\ coronal\\ images\\ demonstrate\\ marked\\ decreased\\ uptake\\ in\\ the\\ posterior\\ parietal\\ and\\ temporal\\ lobes\\ bilaterally\\.\ \(0\)\
\-\ alzheimer\\'s\\ disease\\ based\\ on\\ pet\\ findings\\ and\\ patient\\ history\\.\\ cannot\\ confirm\\ the\\ disease\\ w\\/o\\ brain\\ biopsy\\.\ \(0\)\
\-\ alzheimer\\'s\\ disease\ \(0\)\
\-\ parkinson\\'s\\ disease\\ \\(advanced\\)\ \(0\)\
\-\ fifty\\ seven\\ year\\-old\\ right\\ handed\\ female\\ with\\ worsening\\ dementia\\ versus\\ pseudodementia\\ over\\ approximately\\ two\\ years\\.\ \(0\)\
\-\ although\\ the\\ pet\\ findings\\ are\\ not\\ pathognomic\\ for\\ alzheimer\\'s\\ disease\\,\\ the\\ images\\ are\\ highly\\ predictive\\ of\\ alzheimer\\'s\\ disease\\,\\ particularly\\ with\\ patient\\'s\\ concordant\\ history\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ alzheimer\\:\\ 0\\.5111763589737215\ \(0\)\
\-\ disease\\:\\ 0\\.28116129132103873\ \(0\)\
\-\ pet\\:\\ 0\\.2658593812658499\ \(0\)\
\-\ cholinesterase\\:\\ 0\\.15302394587116983\ \(0\)\
\-\ tacrine\\:\\ 0\\.15302394587116983\ \(0\)\
\-\ cognex\\:\\ 0\\.15302394587116983\ \(0\)\
\-\ pseudodementia\\:\\ 0\\.15302394587116983\ \(0\)\
\-\ pathognomic\\:\\ 0\\.14622254963696463\ \(0\)\
\-\ parkinson\\:\\ 0\\.13459548597763557\ \(0\)\
\-\ fluorodeoxyglucose\\:\\ 0\\.13200971513740437\ \(0\)\
\-\ concordant\\:\\ 0\\.13200971513740437\ \(0\)\
\-\ fifty\\:\\ 0\\.1297698185525117\ \(0\)\
\-\ handed\\:\\ 0\\.12602674009952983\ \(0\)\
\-\ predictive\\:\\ 0\\.12162576136016273\ \(0\)\
\-\ inhibitor\\:\\ 0\\.11712581887013918\ \(0\)\
\-\ the\\:\\ 0\\.11455784398059987\ \(0\)\
\-\ dementia\\:\\ 0\\.11205526670050493\ \(0\)\
\-\ decline\\:\\ 0\\.11134135865897746\ \(0\)\
\-\ cognitive\\:\\ 0\\.11065659798721889\ \(0\)\
\-\ seven\\:\\ 0\\.10319730146662848\ \(0\)\
\-\ stages\\:\\ 0\\.10235841131463844\ \(0\)\
\-\ eg\\:\\ 0\\.10195419158454104\ \(0\)\
\-\ receive\\:\\ 0\\.10079688397179036\ \(0\)\
\-\ findings\\:\\ 0\\.09445049924247088\ \(0\)\
\-\ patient\\:\\ 0\\.09336628952315341\ \(0\)\
\-\ particularly\\:\\ 0\\.09032712792521198\ \(0\)\
\-\ advanced\\:\\ 0\\.08993242013587496\ \(0\)\
\-\ confirm\\:\\ 0\\.0895467868975201\ \(0\)\
\-\ images\\:\\ 0\\.08852298564410606\ \(0\)\
\-\ delay\\:\\ 0\\.08774135708498078\ \(0\)\
\-\ highly\\:\\ 0\\.08565190372449082\ \(0\)\
\-\ versus\\:\\ 0\\.0846260806511301\ \(0\)\
\-\ lobes\\:\\ 0\\.07983598971247334\ \(0\)\
\-\ resolution\\:\\ 0\\.0776362070735562\ \(0\)\
\-\ parietal\\:\\ 0\\.07726548906636123\ \(0\)\
\-\ coronal\\:\\ 0\\.07620009569498847\ \(0\)\
\-\ with\\:\\ 0\\.0749466484064516\ \(0\)\
\-\ sagittal\\:\\ 0\\.07357749869928255\ \(0\)\
\-\ uptake\\:\\ 0\\.07357749869928255\ \(0\)\
\-\ temporal\\:\\ 0\\.07350408804784223\ \(0\)\
\-\ history\\:\\ 0\\.07311575649388677\ \(0\)\
\-\ worsening\\:\\ 0\\.0730702455790035\ \(0\)\
\-\ are\\:\\ 0\\.07261754037291432\ \(0\)\
\-\ marked\\:\\ 0\\.07237121497266984\ \(0\)\
\-\ based\\:\\ 0\\.06931289719144651\ \(0\)\
\-\ early\\:\\ 0\\.0689740107750265\ \(0\)\
\-\ mid\\:\\ 0\\.068862553175048\ \(0\)\
\-\ biopsy\\:\\ 0\\.06707300060655387\ \(0\)\
\-\ although\\:\\ 0\\.06514170707400374\ \(0\)\
\-\ bilaterally\\:\\ 0\\.06381616799861775\ \(0\)\
\-\ will\\:\\ 0\\.061586552938460964\ \(0\)\
\-\ approximately\\:\\ 0\\.06105511544768893\ \(0\)\
\-\ brain\\:\\ 0\\.05965086785114487\ \(0\)\
\-\ and\\:\\ 0\\.059317486799533914\ \(0\)\
\-\ decreased\\:\\ 0\\.05927033795070754\ \(0\)\
\-\ years\\:\\ 0\\.05865469795285082\ \(0\)\
\-\ likely\\:\\ 0\\.057180037210404745\ \(0\)\
\-\ two\\:\\ 0\\.05682399773482897\ \(0\)\
\-\ scan\\:\\ 0\\.05676988701990215\ \(0\)\
\-\ axial\\:\\ 0\\.055272108375271266\ \(0\)\
\-\ high\\:\\ 0\\.054382079754898095\ \(0\)\
\-\ over\\:\\ 0\\.053206040362332174\ \(0\)\
\-\ most\\:\\ 0\\.04979828273811069\ \(0\)\
\-\ demonstrate\\:\\ 0\\.049744889673142924\ \(0\)\
\-\ posterior\\:\\ 0\\.04948044425286229\ \(0\)\
\-\ may\\:\\ 0\\.048152590291458616\ \(0\)\
\-\ in\\:\\ 0\\.04760751642629263\ \(0\)\
\-\ female\\:\\ 0\\.0461732707070063\ \(0\)\
\-\ treatment\\:\\ 0\\.045580676789546595\ \(0\)\
\-\ which\\:\\ 0\\.04350971770555127\ \(0\)\
\-\ not\\:\\ 0\\.03777485313478306\ \(0\)\
\-\ of\\:\\ 0\\.03745094727115535\ \(0\)\
\-\ or\\:\\ 0\\.03328771682854718\ \(0\)\
\-\ right\\:\\ 0\\.031724117066737806\ \(0\)\
\-\ for\\:\\ 0\\.02900191985454505\ \(0\)\
\-\ on\\:\\ 0\\.028899041230430664\ \(0\)\
\-\ to\\:\\ 0\\.02392149978554765\ \(0\)\
\-\ can\\:\\ 0\\.0\ \(0\)\
